Targets of chymase inhibitors

Bibliography

• De Young MB, Nemeth EF, Scarpa A. Measurement of the internal pH of mast cell granules using microvolumetric fluorescence and isotopic techniques. Arch Biochem Biophys 1987;15:222-33
   Google Scholar
• McEuen AR, Sharma B, Walls AF. Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. Biochim Biophys Acta 1995;1267:115-21
   PubMed Web of Science ®Google Scholar
• Takai S, Shiota N, Yamamoto D, Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci 1996;58:591-7
   PubMedGoogle Scholar
• Takai S, Shiota N, Sakaguchi M, Characterization of chymase from human vascular tissues. Clin Chim Acta 1997;265:13-20
   PubMedGoogle Scholar
• Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000;52:11-34
   PubMed Web of Science ®Google Scholar
• MERCATOR Study Group. Dose the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 1992;86:100-10
   PubMed Web of Science ®Google Scholar
• Peters S, Gotting B, Trummel M, Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001;13:93-7
   PubMed Web of Science ®Google Scholar
• Urata H, Healy B, Stewart RW, Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-90
   PubMed Web of Science ®Google Scholar
• Urata H, Kinoshita A, Misono KS, Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-57
   PubMed Web of Science ®Google Scholar
• Takai S, Shiota N, Jin D, Miyazaki M. Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol 1998;32:826-33
   PubMedGoogle Scholar
• Takai S, Sakaguchi M, Jin D, Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta 2001;305:191-5
   PubMedGoogle Scholar
• Uehara Y, Urata H, Sasaguri M, Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension 2000;35:55-60
   PubMed Web of Science ®Google Scholar
• Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14:1738-47
   PubMed Web of Science ®Google Scholar
• Morikawa T, Imanishi M, Suzuki H, Mast cell chymase in the ischemic kidney of severe unilateral renovascular hypertension. Am J Kidney Dis 2005;45:e45-50
   Google Scholar
• Welker P, Kramer S, Groneberg DA, Increased mast cell number in human hypertensive nephropathy. Am J Physiol Renal Physiol 2008;295:F1103-9
   Google Scholar
• Takai S, Jin D, Sakaguchi M, A novel chymase inhibitor, BCEAB (4-[1-{[bis- (4-methyl-phenyl)-methyl]-carbamoyl}-3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid) suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 2003;305:17-23
   PubMed Web of Science ®Google Scholar
• Maruichi M, Takai S, Sugiyama T, Role of chymase on growth of cultured canine Tenon's capsule fibroblasts and scarring in a canine conjunctival flap model. Exp Eye Res 2004;79:111-18
   PubMedGoogle Scholar
• Fang KC, Raymond WW, Blount JL, Caughey GH. Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain. J Biol Chem 1997;272:25628-35
   PubMed Web of Science ®Google Scholar
• Furubayashi K, Takai S, Jin D, Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm. Clin Chim Acta 2008;388:214-16
   PubMedGoogle Scholar
• Murakami M, Karnik SS, Husain A. Human prochymase activation. A novel role for heparin in zymogen processing. J Biol Chem 1995;270:2218-23
   PubMed Web of Science ®Google Scholar
• Wolters PJ, Pham CT, Muilenburg DJ, Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice. J Biol Chem 2001;276:18551-6
   PubMed Web of Science ®Google Scholar
• De Young MB, Nemeth EF, Scarpa A. Measurement of the internal pH of mast cell granules using microvolumetric fluorescence and isotopic techniques. Arch Biochem Biophys 1987;254:222-33
   PubMedGoogle Scholar
• McEuen AR, Sharma B, Walls AF. Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. Biochim Biophys Acta 1995;1267:115-21
   PubMed Web of Science ®Google Scholar
• Schechter NM, Sprows JL, Schoenberger OL, Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J Biol Chem 1989;264:21308-15
   PubMed Web of Science ®Google Scholar
• Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation 1997;95:1455-63
   PubMed Web of Science ®Google Scholar
• Takai S, Jin D, Sakaguchi M, Miyazaki M. Chymase-dependent angiotensin II formation in human vascular tissue. Circulation 1999;100:654-8
   PubMedGoogle Scholar
• Takai S, Yuda A, Jin D, Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett 2000;467:141-4
   PubMedGoogle Scholar
• Nishimoto M, Takai S, Kim S, Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 2001;104:1274-9
   PubMed Web of Science ®Google Scholar
• Wintroub BU, Schechter NM, Lazarus GS, Angiotensin I conversion by human and rat chymotryptic protainases. J Invest Dermatol 1984;83:336-9
   PubMed Web of Science ®Google Scholar
• Takai S, Shiota N, Kobayashi S, Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 1997;412:86-90
   PubMedGoogle Scholar
• Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim Biophys Acta 2000;1480:245-57
   PubMedGoogle Scholar
• Akasu M, Urata H, Kinoshita A, Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 1998;32:514-20
   PubMed Web of Science ®Google Scholar
• Taipale J, Lohi J, Saarinen J, Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995;270:4689-96
   PubMed Web of Science ®Google Scholar
• Tchougounova E, Lundequist A, Fajardo I, A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005;280:9291-6
   PubMed Web of Science ®Google Scholar
• Thompson RW, Holmes DR, Mertens RA, Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995;96:318-26
   PubMed Web of Science ®Google Scholar
• Freestone T, Turner RJ, Coady A, Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995;15:1145-51
   PubMed Web of Science ®Google Scholar
• Nishimoto M, Takai S, Fukumoto H, Increased local angiotensin II formation in aneurysmal aorta. Life Sci 2002;71:2195-205
   PubMed Web of Science ®Google Scholar
• Ihara M, Urata H, Kinoshita A, Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999;33:1399-405
   PubMed Web of Science ®Google Scholar
• Tsunemi K, Takai S, Nishimoto M, A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1- phenyl-7-(2-pyridyloxy)]-2-heptyl] acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther 2004;309:879-83
   PubMedGoogle Scholar
• Furubayashi K, Takai S, Jin D, The significance of chymase in the progression of abdominal aortic aneurysms in dogs. Hypertens Res 2007;30:349-57
   PubMedGoogle Scholar
• Inoue N, Muramatsu M, Jin D, Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis 2009;204:359-64
   PubMedGoogle Scholar
• Sun J, Zhang J, Lindholt JS, Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 2009;120:973-82
   PubMed Web of Science ®Google Scholar
• Cipollone F, Fazia M, Iezzi A, Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004;109:1482-8
   PubMedGoogle Scholar
• Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 2000;59:245-54
   PubMed Web of Science ®Google Scholar
• Sorbi D, Fadly M, Hicks R, Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int 1993;44:1266-72
   PubMed Web of Science ®Google Scholar
• Yamamoto D, Takai S, Jin D, Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol 2007;43:670-6
   PubMed Web of Science ®Google Scholar
• Takai S, Jin D, Ohzu M, Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocin-induced diabetes. J Pharmacol Sci 2009;110:459-65
   PubMedGoogle Scholar
• Kinoshita A, Urata H, Bumpus FM, Husain A. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J Biol Chem 1991;266:19192-7
   PubMed Web of Science ®Google Scholar
• Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14:1738-47
   PubMed Web of Science ®Google Scholar
• Maeda Y, Inoguchi T, Takei R, Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol 2010;299:F1328-38
   Google Scholar
• Koka V, Wang W, Huang XR, Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation 2006;113:1353-60
   PubMed Web of Science ®Google Scholar
• Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res 2007;101:455-64
   PubMed Web of Science ®Google Scholar
• Otani A, Takagi H, Oh H, Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci 2000;41:1192-9
   PubMed Web of Science ®Google Scholar
• Fukumoto M, Takai S, Ishizaki E, Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model. Curr Eye Res 2008;33:885-91
   PubMed Web of Science ®Google Scholar
• Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 1998;83:832-40
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, Ligtvoet N, Twaalfhoven H, Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 1999;48:2446-53
   PubMed Web of Science ®Google Scholar
• Stitt AW, Li YM, Gardiner TA, Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997;150:523-31
   PubMed Web of Science ®Google Scholar
• Li L, Renier G. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism 2006;55:1516-23
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Okuno T, Fukuhara M, Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res 2007;85:406-12
   PubMed Web of Science ®Google Scholar
• Robinson GS, Pierce EA, Rook SL, Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996;93:4851-6
   PubMed Web of Science ®Google Scholar
• Bhisitkul RB, Robinson GS, Moulton RS, An antisense oligodeoxynucleotide against vascular endothelial growth factor in a nonhuman primate model of iris neovascularization. Arch Ophthalmol 2005;123:214-19
   PubMedGoogle Scholar
• Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 1999;117:498-503
   PubMed Web of Science ®Google Scholar
• Eghbali M, Tomek R, Woods C, Bhambi B. Cardiac fibroblasts are predisposed to convert into myocyte phenotype: specific effect of transforming growth factor beta. Proc Natl Acad Sci USA 1991;88:795-9
   PubMed Web of Science ®Google Scholar
• Li RK, Li G, Mickle DA, Overexpression of transforming growth factor-?beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997;96:874-81
   PubMed Web of Science ®Google Scholar
• Patella V, Marino I, Arbustini E, Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 1998;97:971-8
   PubMed Web of Science ®Google Scholar
• Kuwahara F, Kai H, Tokuda K, Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 2004;43:739-45
   PubMed Web of Science ®Google Scholar
• Nakamura F, Nagano M, Kobayashi R, Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters. Am J Physiol 1994;267:H2297-304
   Google Scholar
• Palaniyandi SS, Nagai Y, Watanabe K, Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp Biol Med 2007;232:1213-21
   Google Scholar
• Powell EE, Cooksley WG, Hanson R, The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Leone N, Vanni E, Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Hines JE, Walls AF, Intrahepatic mast cells in chronic liver diseases. Hepatology 1995;22:1175-81
   PubMedGoogle Scholar
• Armbrust T, Batusic D, Ringe B, Ramadori G. Mast cells distribution in human liver disease and experimental rat liver fibrosis. Indications for mast cell participation in development of liver fibrosis. J Hepatol 1997;26:1042-54
   PubMed Web of Science ®Google Scholar
• Matsunaga Y, Kawasaki H, Terada T. Stromal mast cells and nerve fibers in various chronic liver diseases: relevance to hepatic fibrosis. Am J Gastroenterol 1999;94:1923-32
   PubMed Web of Science ®Google Scholar
• Uno M, Kurita S, Misu H, Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. Hepatology 2008;48:109-18
   PubMedGoogle Scholar
• Tashiro K, Takai S, Jin D, Chymase inhibitor prevents the nonalcoholic steatohepatitis in hamsters fed a methionine- and choline-deficient diet. Hepatol Res 2010;40:514-23
   PubMedGoogle Scholar
• Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991;88:6642-6
   PubMed Web of Science ®Google Scholar
• Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993;48:959-66
   PubMed Web of Science ®Google Scholar
• Sukenaga Y, Kamoshita K, Takai S, Miyazaki M. Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities. Jpn J Pharmacol 2002;90:218-22
   PubMedGoogle Scholar
• Sakaguchi M, Takai S, Jin D, A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. Eur J Pharmacol 2004;493:173-6
   PubMedGoogle Scholar
• Tomimori Y, Muto T, Saito K, Involvement of mast cell chymase in bleomycin-induced pulmonary fibrosis in mice. Eur J Pharmacol 2003;478:179-85
   PubMedGoogle Scholar
• Takato H, Yasui M, Ichikawa Y, The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice. Exp Lung Res 2011: published online 4 December 2010 doi:10.3109/01902148.2010.520815
   Google Scholar
• Komeda K, Jin D, Takai S, Significance of chymase-dependent angiotensin II formation in the progression of human liver fibrosis. Hepatol Res 2008;38:501-10
   PubMedGoogle Scholar
• Ikura Y, Ohsawa M, Shirai N, Expression of angiotensin II type 1 receptor in human cirrhotic livers: its relation to fibrosis and portal hypertension. Hepatol Res 2005;32:107-16
   PubMedGoogle Scholar
• Rimola A, Londono MC, Guevara G, Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004;78:686-91
   PubMed Web of Science ®Google Scholar
• Komeda K, Takai S, Jin D, Chymase inhibition attenuates tetrachloride-induced liver fibrosis in hamsters. Hepatol Res 2010;40:832-40
   PubMedGoogle Scholar
• Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006;318:933-8
   PubMed Web of Science ®Google Scholar
• Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67
   PubMed Web of Science ®Google Scholar
• Ishida K, Takai S, Murano M, Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther 2008;324:422-6
   PubMed Web of Science ®Google Scholar
• Castaneda FE, Walia B, Vijay-Kumar M, Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 2005;129:1991-2008
   PubMed Web of Science ®Google Scholar
• Allison MC, Howatson AG, Torrance CJ, Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749-54
   PubMed Web of Science ®Google Scholar
• Maiden L, Thjodleifsson B, Theodors A, A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172-8
   PubMed Web of Science ®Google Scholar
• Kakimoto K, Takai S, Murano M, Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats. J Pharmacol Exp Ther 2010;332:684-9
   PubMedGoogle Scholar
• Terakawa M, Tomimori Y, Goto M, Fukuda Y. Mast cell chymase induces expression of chemokines for neutrophils in eosinophilic EoL-1 cells and mouse peritonitis eosinophils. Eur J Pharmacol 2006;538:175-81
   PubMedGoogle Scholar
• Tani K, Ogushi F, Kido H, Chymase is a potent chemoattractant for human monocytes and neutrophils. J Leukoc Biol 2000;67:585-9
   PubMed Web of Science ®Google Scholar
• Thompson RW. Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem. Curr Opin Cardiol 1996;11:504-18
   PubMedGoogle Scholar
• Ballotta E, Toniato A. Small abdominal aortic aneurysms. N Engl J Med 2002;347:1112-15
   PubMedGoogle Scholar
• Muramatsu M, Katada J, Hayashi I, Majima M. Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 2000;275:5545-52
   PubMed Web of Science ®Google Scholar
• Muramatsu M, Yamada M, Takai S, Miyazaki M. Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin-dependent pathway in hamster sponge granulomas. Br J Pharmacol 2002;137:554-60
   PubMedGoogle Scholar
• Sjolie AK, Klein R, Porta M, Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008;372:1385-93
   PubMed Web of Science ®Google Scholar